Table 2.

Outcome measures for completers at each assessment

Outcome variable	WL			CT‐PTSD			Group effecta
	M	SD	n	M	SD	n
PTSD symptoms (CPTSDI)
Pre	11.7	2.9	15	11.9	3.2	14	F (1,28) = .01, p = .92
Post	10.2	4.3	13	2.6	3.6	13	F (1,25) = 28.90, p < .0001
6MFU				1.5	2.6	13
12MFU				2.1	3.6	13
PTSD severity (CPSS)
Pre	30.1	11.5	15	31.1	7.9	14	F (1,28) = .08, p = .78
Post	24.3	16.0	13	6.2	10.5	13	F (1,25) = 16.36, p < .0006
6MFU				5.2	8.6	13
12MFU				5.5	6.2	13
Depression (MFQ)
Pre	27.8	16.6	15	29.3	11.6	14	F (1,28) = .08, p = .78
Post	25.0	21.5	13	11.2	14.0	13	F (1,25) = 4.66, p < .04
6MFU				11.3	10.9	13
12MFU				8.2	7.2	13
Anxiety (SCAS)
Pre	54.0	25.8	15	45.6	18.4	14	F (1,28) = 1.01, p = .32
Post	49.5	34.5	13	19.5	18.0	13	F (1,25) = 7.50, p < .02
6MFU				16.2	15.4	13
12MFU				14.2	10.1	13
Functioning (CGAS)
Pre	58.5	10.5	15	57.3	8.6	14	F (1,28) = .12, p = .73
Post	55.2	13.8	13	77.4	14.2	13	F (1,25) = 17.44, p < .0004
Emotional difficulties (SDQ)
Pre	6.3	3.3	15	5.8	2.4	13	F (1,27) = .23, p = .64
Post	5.6	3.5	11	3.3	2.1	13	F (1,22) = 8.53, p < .01
Conduct problems (SDQ)
Pre	4.2	2.3	15	2.9	2.0	13	F (1,27) = 2.43, p = .13
Post	4.4	2.8	11	1.8	1.6	11	F (1,22) = 6.26, p < .03
Hyperactivity (SDQ)
Pre	6.3	2.8	15	5.4	3.1	13	F (1,27) = .64, p = .43
Post	6.2	2.4	11	3.2	2.2	12	F (1,22) = 18.28, p < .0004

Pre = pretreatment (i.e. at randomization); Post = post‐CT‐PTSD/WL (Week 11); 6MFU = 6‐month follow‐up; 12MFU = 12‐month follow‐up; CPSS, Child PTSD Symptom Scale; CT‐PTSD, Cognitive Therapy for PTSD; SDQ, Strengths and Difficulties Questionnaire; WL, waiting list.

^aAt pretreatment, one‐way ANOVA; at posttreatment, one‐way ANCOVA (pretreatment scores as covariates).